Anthony J. Maddaluna, Executive Vice President and President of Pfizer Global Supply to Retire

• Kirsten Lund-Jurgensen to succeed Maddaluna

NEW YORK--(BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) today announced that Anthony J. Maddaluna, Executive Vice President and President of Pfizer Global Supply will retire from the company after more than 41 years with Pfizer.

“I have had the privilege of working with Tony during much of his career, and he has been a valuable partner to me,” said Ian Read, chairman and chief executive officer, Pfizer. “Tony has continually demonstrated a steadfast commitment to Pfizer and our mission. His focus on quality, compliance and customer service has established Pfizer Global Supply as an industry leading supply organization that is highly respected by internal and external stakeholders. I know I join all Pfizer colleagues in thanking Tony for his tireless efforts and wishing him and his family all the best as he embarks on the next stage of his life.”

Mr. Maddaluna began his career at Pfizer in 1975, and throughout his career with the company has held several positions of increasing responsibility prior to being named President of Pfizer Global Supply in 2011.

“I have thoroughly enjoyed my career at Pfizer and being part of the company’s executive leadership team,” said Tony Maddaluna. “Based on more than four decades at Pfizer, I am truly proud of our dedicated colleagues who have discovered, developed and delivered the high quality vaccines and medicines that combat the world’s most pressing healthcare challenges today.”

Kirsten Lund-Jurgensen will succeed Mr. Maddaluna and has been named Executive Vice President and President of Pfizer Global Supply, effective December 30, 2016. She is currently Vice President, Innovative Health Product Portfolio Management and Consumer Operations. Ms. Lund-Jurgensen will report directly to Mr. Read and join Pfizer’s Executive Leadership team.

“Kirsten has already been playing a leadership role in Pfizer Global Supply, and her wealth of knowledge, extensive operational experience and solid track record of delivering results make her an excellent choice for the leader of our supply organization,” stated Read.

Ms. Lund-Jurgensen joined the Company in 1999 as Vice President, Global Supply Chain Management, Pharmaceuticals. Prior to Pfizer, she was with SmithKline Beecham in Germany, Australia, and the United States, working in several operational roles. Ms. Lund-Jurgensen is a pharmacist and holds a Ph.D. in Pharmaceutical Biology from Freiburg University in Germany.

About Pfizer:

At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products. Our global portfolio includes medicines and vaccines as well as many of the world's best-known consumer health care products. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 150 years, Pfizer has worked to make a difference for all who rely on us. For more information, please visit us at www.pfizer.com. In addition, to learn more, follow us on Twitter at @Pfizer and @Pfizer_News, LinkedIn, YouTube and like us on Facebook at Facebook.com/Pfizer.

View source version on businesswire.com: http://www.businesswire.com/news/home/20161121005723/en/

Pfizer Inc.
Media:
Joan Campion, 212-733-2798
or
Investor Relations:
Ryan Crowe, 212-733-8160

Source: Pfizer Inc.

You May Also Be Interested In

• European Commission Approves Pfizer’s EMBLAVEO® for Patients with Multidrug-Resistant Infections and Limited Treatment Options
• Tharimmune Announces Option Agreement for Key Technologies for Generating HER2/HER3 Antibody Drug Conjugates (ADCs)
• Lisata Therapeutics and Qilu Pharmaceutical Announce First Patient Treated in Qilu’s Phase 2 Trial in China of LSTA1 in Patients with Metastatic Pancreatic Ductal Adenocarcinoma